Novo Nordisk's experimental combination therapy CagriSema demonstrated superior weight loss and blood sugar control compared to semaglutide alone in a Phase 3 trial. The drug combines the GLP-1 agonist semaglutide with cagrilintide, an amylin receptor agonist, resulting in a 14.2% reduction in body weight over 68 weeks. These results suggest a potential new standard for treating type 2 diabetes and obesity.